Protagonist Therapeutics (PTGX) Retained Earnings (2015 - 2026)
Protagonist Therapeutics' (PTGX) quarterly Retained Earnings came in at -$269000.0 in Q1 2026, up 99.92% year-on-year from -$134551.4 in Q1 2025, and up 99.94% quarter-over-quarter from -$470.7 million in Q4 2025.
Protagonist Therapeutics (PTGX) Retained Earnings (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has disclosed Retained Earnings across 12 years of filings, most recently posting -$269000.0 for Q1 2026.
- Retained Earnings for Q1 2026 came in at -$269000.0, up 99.92% year-over-year; the trailing twelve-month figure through Mar 2026 was -$269000.0 (up 99.92% YoY), and the FY2025 annual result was -$470.7 million, down 573889.02% from the prior year.
- Retained Earnings came in at -$269000.0 for Q1 2026 at Protagonist Therapeutics, up from -$470.7 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $525000.0 in Q3 2025 to a low of -$643.0 million in Q3 2023.
- The 5-year median for Retained Earnings is -$386.9 million (2025), against an average of -$284.0 million.
- Peak annual rise in Retained Earnings reached 100.11% in 2025, while the deepest fall reached 573889.02% in 2025.
- Protagonist Therapeutics' Retained Earnings stood at -$359000.0 in 2022, then plunged by 171406.96% to -$615.7 million in 2023, then surged by 99.99% to -$82000.0 in 2024, then slumped by 573889.02% to -$470.7 million in 2025, then jumped by 99.94% to -$269000.0 in 2026.
- The last three Retained Earnings figures came in at -$269000.0 (Q1 2026), -$470.7 million (Q4 2025), and $525000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Protagonist Therapeutics | 7.35 Bn | 7.35 Bn | - | -269,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -269,000.00 |
| Dec 31, 2025 | -470.67 Mn |
| Sep 30, 2025 | 525,000.00 |
| Jun 30, 2025 | -386.95 Mn |
| Mar 31, 2025 | -352.18 Mn |
| Dec 31, 2024 | -82,000.00 |
| Sep 30, 2024 | -472.20 Mn |
| Jun 30, 2024 | -438.99 Mn |
| Mar 31, 2024 | -408.40 Mn |
| Dec 31, 2023 | -615.71 Mn |
| Sep 30, 2023 | -643.00 Mn |
| Jun 30, 2023 | -608.90 Mn |
| Mar 31, 2023 | -122,000.00 |
| Dec 31, 2022 | -359,000.00 |
| Sep 30, 2022 | -480,000.00 |
| Jun 30, 2022 | -720,000.00 |
| Mar 31, 2022 | -430.29 Mn |
| Dec 31, 2021 | -409.36 Mn |
| Sep 30, 2021 | -204,000.00 |
| Jun 30, 2021 | -59,000.00 |